SLC5A2 and diabetes mellitus: The Canagliflozin and Kidney Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study was the first study of an SGLT-2 inhibitor to have kidney outcomes in its primary composite end point.20